Literature DB >> 17381625

Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions.

Miguel Lozano1, Ana Galan, Roberto Mazzara, Laurence Corash, Ginés Escolar.   

Abstract

BACKGROUND: Amotosalen plus ultraviolet A light photochemical treatment (PCT) inactivates high titers of bacteria, and other pathogens, in platelet concentrates (PCs) potentially allowing the storage of platelets (PLTs) for up to 7 days. Adhesion and aggregation of PLTs to injured vascular surfaces are critical aspects of PLT hemostatic function. STUDY DESIGN AND METHODS: Two ABO-identical leukoreduced buffy coat-derived PCs in additive solution were mixed and divided: one-half underwent PCT (PCT-PCs) and the other was kept as a control (C-PCs); both were stored under standard conditions. The total number of paired PCs studied was nine. Samples were taken on Day 1 (before PCT) and after 5 and 7 days of storage. The adhesion and aggregation capacities were evaluated under flow conditions in a ex vivo perfusion model.
RESULTS: Compared to control, PCT resulted in a decrease in PLT count of 6.5 percent (p = 0.004) and 10.2 percent (p = 0.008) after 5 and 7 days' storage, respectively (n = 9). PLT interaction with subendothelium was mainly in form of adhesion. The surface covered by PCT PLTs on Day 1 was 26.0 +/- 4.2 percent (mean +/- SEM). On Day 5, PCT-PCs showed a covered surface of 20.9 +/- 2.2 percent, and the C-PCs, 20.6 +/- 1.6 percent. After 7 days, PCT-PCs produced a nonsignificant higher PLT deposition compared to control (27.1 +/- 2.9% vs. 21.2 +/- 2.8%, p = 0.06).
CONCLUSION: PCT of PCs and storage up to 7 days was associated with a 10.2 percent decrease in PLT count due to processing losses compared to C-PC. PLT adhesive and aggregating capacities under flow conditions of PCT-PCs were similar to C-PCs and remained well preserved for up to 7 days of storage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17381625     DOI: 10.1111/j.1537-2995.2007.01169.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

1.  Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™

Authors:  Johannes Irsch; Lily Lin
Journal:  Transfus Med Hemother       Date:  2011-01-27       Impact factor: 3.747

2.  In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step.

Authors:  Mélanie Abonnenc; Giona Sonego; Julie Kaiser-Guignard; David Crettaz; Michel Prudent; Jean-Daniel Tissot; Niels Lion
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

Review 3.  Current methods for the reduction of blood-borne pathogens: a comprehensive literature review.

Authors:  Susanne M Picker
Journal:  Blood Transfus       Date:  2013-03-14       Impact factor: 3.443

4.  Amotosalen/UVA pathogen inactivation technology reduces platelet activability, induces apoptosis and accelerates clearance.

Authors:  Beatrice Hechler; Catherine Ravanat; Christian Gachet
Journal:  Haematologica       Date:  2017-12       Impact factor: 9.941

Review 5.  Ultraviolet-Based Pathogen Inactivation Systems: Untangling the Molecular Targets Activated in Platelets.

Authors:  Peter Schubert; Lacey Johnson; Denese C Marks; Dana V Devine
Journal:  Front Med (Lausanne)       Date:  2018-05-07

Review 6.  Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: An updated view during a pandemic.

Authors:  Gines Escolar; Maribel Diaz-Ricart; Jeffrey McCullough
Journal:  Transfusion       Date:  2021-12-06       Impact factor: 3.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.